Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

UHRF1 poly-auto-ubiquitination induced by the anti-cancer drug, thymoquinone, is involved in the DNA repair machinery recruitment.

Almalki NAR, Sabir JSM, Ibrahim A, Alhosin M, Asseri AH, Albiheyri RS, Zari AT, Bahieldin A, Javed A, Mély Y, Hamiche A, Mousli M, Bronner C

Int J Biochem Cell Biol. 2024 04 20;:106582

Natural and Synthetic Anticancer Epidrugs Targeting the Epigenetic Integrator UHRF1.

Ashraf W, Ahmad T, Reynoird N, Hamiche A, Mély Y, Bronner C, Mousli M

Molecules. 2023 08 10;28(16):

Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells.

Ciaco S, Mazzoleni V, Javed A, Eiler S, Ruff M, Mousli M, Mori M, Mély Y

Bioorg Chem. 2023 05 22;137:106616

Tannin extract from maritime pine bark exhibits anticancer properties by targeting the epigenetic UHRF1/DNMT1 tandem leading to the re-expression of .

Ashraf W, Ahmad T, Almalki NAR, Krifa M, Zaayter L, Pizzi A, Muller CD, Hamiche A, Mély Y, Bronner C, Mousli M

Food Funct. 2021 Dec 13;:

TIP60 governs the auto‑ubiquitination of UHRF1 through USP7 dissociation from the UHRF1/USP7 complex.

Ahmad T, Ashraf W, Ibrahim A, Zaayter L, Muller CD, Hamiche A, Mély Y, Bronner C, Mousli M

Int J Oncol. 2021 Nov;59(5):

S-Protected thiolated nanostructured lipid carriers exhibiting improved mucoadhesive properties.

Arshad S, Masood-Ur-Rehman, Hussain Asim M, Nazir I, Shahzadi I, Mousli M, Bernkop-Schnürch A

Int J Pharm. 2020 09 25;587:119690

A molecular tool targeting the base flipping activity of human UHRF1.

Zaayter L, Mori M, Ahmad T, Ashraf W, Boudier C, Kilin V, Gavvala K, Richert L, Eiler S, Ruff M, Botta M, Bronner C, Mousli M, Mely Y

Chemistry. 2019 Jul 19;:

Coordinated Dialogue between UHRF1 and DNMT1 to Ensure Faithful Inheritance of Methylated DNA Patterns.

Bronner C, Alhosin M, Hamiche A, Mousli M

Genes (Basel). 2019 Jan 18;10(1):

Thymoquinone challenges UHRF1 to commit auto-ubiquitination: a key event for apoptosis induction in cancer cells.

Ibrahim A, Alhosin M, Papin C, Ouararhni K, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mély Y, Hamiche A, Mousli M, Bronner C

Oncotarget. 2018 Jun 19;9(47):28599-28611

Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy.

Choudhry H, Zamzami MA, Omran Z, Wu W, Mousli M, Bronner C, Alhosin M

Oncol Lett. 2018 Jan;15(1):3-10

Interaction of the epigenetic integrator UHRF1 with the MYST domain of TIP60 inside the cell.

Ashraf W, Bronner C, Zaayter L, Ahmad T, Richert L, Alhosin M, Ibrahim A, Hamiche A, Mely Y, Mousli M

J. Exp. Clin. Cancer Res.. 2017 12 21;36(1):188

The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer.

Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C, Mousli M

Oncotarget. 2017 Aug;8(31):51946-51962

The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer.

Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C, Mousli M

Oncotarget. 2017 Apr;:

Dynamics of Methylated Cytosine Flipping by UHRF1.

Kilin V, Gavvala K, Barthes NP, Michel BY, Shin D, Boudier C, Mauffret O, Yashchuk V, Mousli M, Ruff M, Granger F, Eiler S, Bronner C, Tor Y, Burger A, Mély Y

J. Am. Chem. Soc.. 2017 Feb;139(6):2520-2528

Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer.

Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, Mousli M, Bronner C

J. Exp. Clin. Cancer Res.. 2016 Nov;35(1):174

CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells.

Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, Andre P, Mely Y, Mousli M, Gies JP

Anticancer Res. 2015 Jan;35(1):149-57.

Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis.

Bronner C, Krifa M, Mousli M

Biochem Pharmacol. 2013 Dec 15;86(12):1643-9

Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1.

Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S, Bronner C

Biochem Biophys Res Commun. 2013 Jan 4;430(1):208-12

Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation.

Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, Mely Y, Bronner C, Mousli M

J Exp Clin Cancer Res. 2013 May 20;32:30

Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1.

Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S, Bronner C

Biochem Biophys Res Commun. 2012 Jul 3.

Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, Bronner C

J Exp Clin Cancer Res. 2011 Apr 15;30:41.

Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum.

Akaddar A, Doderer-Lang C, Marzahn MR, Delalande F, Mousli M, Helle K, Van Dorsselaer A, Aunis D, Dunn BM, Metz-Boutigue MH, Candolfi E

Cell Mol Life Sci. 2010 Mar;67(6):1005-15

UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activity.

Achour M, Fuhrmann G, Alhosin M, Ronde P, Chataigneau T, Mousli M, Schini-Kerth VB, Bronner C

Biochem Biophys Res Commun. 2009 Dec 18;390(3):523-8

A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.

Unoki M, Bronner C, Mousli M

Radiat Res. 2008 Feb;169(2):240-4.

The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle.

Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N, Abbady AQ, Siffert JC, Mathieu E, Muller CD, Bronner C

Oncogene. 2005 Nov 10;24(49):7337-45.

Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of the topoisomerase IIalpha gene expression.

Hopfner R, Mousli M, Garnier JM, Redon R, du Manoir S, Chatton B, Ghyselinck N, Oudet P, Bronner C

Gene. 2001 Mar 21;266(1-2):15-23.

M2-muscarinic receptors: how does ligand binding affinity relate to intrinsic activity?

Van Gelderen JG, Daeffler L, Scherrer D, Mousli M, Landry Y, Gies JP

J. Recept. Signal Transduct. Res.. ;16(1-2):135-48

Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase II alpha expression.

Hopfner R, Mousli M, Oudet P, Bronner C

Anticancer Res.. ;22(6A):3165-70

Dr MOUSLI Marc

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Publications